A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
| Autor: | Gerard Sanacora, Samuel T. Wilkinson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Ganaxolone Traxoprodil Glutamic Acid Article 03 medical and health sciences 0302 clinical medicine Drug Discovery Monoaminergic medicine Rapastinel Animals Humans gamma-Aminobutyric Acid Pharmacology business.industry Mood Disorders Glutamate receptor medicine.disease Antidepressive Agents Riluzole 030104 developmental biology Mood disorders 030220 oncology & carcinogenesis business Neuroscience Apimostinel medicine.drug |
| Popis: | Mood disorders represent the largest cause of disability worldwide. The monoaminergic deficiency hypothesis, which has dominated the conceptual framework for researching the pathophysiology of mood disorders and the development of novel treatment strategies, cannot fully explain the underlying neurobiology of mood disorders. Mounting evidence collected over the past two decades suggests the amino acid neurotransmitter systems (glutamate and GABA) serve central roles in the pathophysiology of mood disorders. Here, we review progress in the development of compounds that act on these systems as well as their purported mechanisms of action. We include glutamate-targeting drugs, such as racemic ketamine, esketamine, lanicemine (AZD6765), traxoprodil (CP-101,606), EVT-101, rislenemdaz (CERC-301/MK-0657), AVP-786, AXS-05, rapastinel (formerly GLYX-13), apimostinel (NRX-1074/AGN-241660), AV-101, NRX-101, basimglurant (RO4917523), decoglurant (RG-1578/RO4995819), tulrampator (CX-1632/S-47445), and riluzole; and GABA-targeting agents, such as brexanolone (SAGE-547), ganaxolone, and SAGE-217. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|